{"id":"prazepam","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Alcohol intoxication","Behavioral Disorders","Borderline personality disorder","Coma","Decreased respiratory function","Depressive disorder","Disease of liver","Disorder of lung","Hypoalbuminemia","Kidney disease","Porphyria","Pregnancy, function","Psychotic disorder","Shock","Sleep apnea","Sleep automatism","Substance abuse","Suicidal thoughts"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL969","moleculeType":"Small molecule","molecularWeight":"324.81"},"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:37:39.896190","allNames":"prazene","offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"GABA-A receptor alpha-1/beta-2/gamma-2","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T00:37:43.763Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Anxiety","diseaseId":"anxiety","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Insomnia","diseaseId":"insomnia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["generics(1)","patents(0)","modality→Small Molecule"],"labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":202,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Usl Pharma"],"phase":"marketed","status":"approved","brandName":"Prazene","genericName":"PRAZEPAM","companyName":"Parke Davis","companyId":"","modality":"Small molecule","firstApprovalDate":"1982","aiSummary":"Prazepam, also known as PRAZEPAM, is a small molecule prazepam drug class targeting the GABA-A receptor alpha-1/beta-2/gamma-2. It is used to treat anxiety and insomnia. Originally developed by Parke Davis, it is currently owned by the same company and is off-patent with no active Orange Book patents. Prazepam is available as a generic medication with a single generic manufacturer.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}